Company intelligence / Profile preview
Ripple Therapeutics
Toronto, Ontario, Canadarippletherapeutics.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The RIPPLE-1 clinical trial demonstrated safety, efficacy, and duration of their Dexamethasone IVT implant in retina patients with RVO and DME. Glaucoma implant preclinical data confirmed safety and efficacy, with long-term safety established after second implant administration.
- Therapeutic areas
- Ophthalmology
- Modalities
- Sustained drug delivery implantsProdrugs
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
03
Partnerships
AbbVie (NYSE: ABBV)Glaukos Corporation (NYSE: GKOS)
Beyond the preview
Go deeper on Ripple Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ripple Therapeutics.